Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asparaginase erythrocyte encapsulated - PHAXIAM Therapeutics

Next Previous
X
Search
Drug Profile

Asparaginase erythrocyte encapsulated - PHAXIAM Therapeutics

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase-PHAXIAM Therapeutics; GRASPA; L-asparaginase loaded erythrocytes-PHAXIAM Therapeutics

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ERYtech Pharma
  • Developer PHAXIAM Therapeutics
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II/III Triple negative breast cancer
  • Phase II Acute myeloid leukaemia
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(First-line therapy, Metastatic disease) in Unknown (IV, Infusion)
  • 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top